Leadership
-
Permission granted by Immunocore
Q&A // First 90 DaysLilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO
Travis Coy is using his Big Pharma bona fides to prioritize business development at the diversified and growing company.
By Michael Gibney • Feb. 20, 2025 -
Stock via Getty Images
Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split
The two companies will let their long-running contract expire this year, and drugmakers will need to decide which is the best platform for them in a changing marketplace.
By Michael Gibney • Feb. 13, 2025 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
cagkansayin via Getty Images
With uncertainty roiling Big Pharma, execs are placing lower-risk bets
The market has been no less demanding for pharma giants as 2025 begins, but last year’s strategies are paying off.
By Michael Gibney • Feb. 6, 2025 -
Win McNamee via Getty Images
RFK Jr. will face these critical tests if confirmed as head of the HHS
After a Senate committee advanced President Trump’s nominee to lead HHS, Robert F. Kennedy Jr. is poised to secure the top job at the nation’s healthcare agency.
By Amy Baxter • Feb. 5, 2025 -
David McNew/Getty Images via Getty Images
Looming USAID shutdown threatens global health presence and a legacy of medical foreign aid
As President Trump and his cohorts plan to shut down the U.S. Agency for International Development, here’s what that could mean for global health and the drugmaking industry.
By Michael Gibney • Feb. 4, 2025 -
Stock via Getty Images
Year in PreviewPharma’s forecast for 2025: Sowing seeds of a rebound
Despite regulatory uncertainty, pharma is bouncing back from a market slump and is being fueled by innovation.
By Meagan Parrish • Jan. 31, 2025 -
Win McNamee via Getty Images
RFK Jr. faces reconciliation of past vaccine statements at Senate HHS hearing
“Are you supportive of these onesies?” Sen. Bernie Sanders asked Kennedy, pointing to infant clothing stamped with anti-vaccine slogans — and more from yesterday’s confirmation hearing.
By Michael Gibney • Jan. 30, 2025 -
Permission granted by Klein Hersh
Executive hiring changes reflect a broader biotech comeback
Executive hiring shifts are often indicators of wider trends in the market. Here’s how the hiring landscape for pharma leaders is changing.
By Alexandra Pecci • Jan. 29, 2025 -
iStock via Getty Images
Bringing drugs to market has ‘never been more challenging,’ and pharma is learning to adapt
As changes to the U.S. regulatory foundation take hold, pharmas need to change their strategies to keep innovation — and the bottom line — above the surface.
By Michael Gibney • Jan. 28, 2025 -
Anna Moneymaker via Getty Images
Musk’s rare disease torpedo, hospitals’ pharma fix and other policies leaders are tracking
There’s more to pharma's regulatory story in 2025 than just the IRA.
By Meagan Parrish • Jan. 17, 2025 -
Stock via Getty Images
Opinion // Year in PreviewPharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials
Coming changes that could impact pharma from drug development to launch.
By Meagan Parrish • Jan. 10, 2025 -
Permission granted by Candel Therapeutics
Q&A // Biotech SpotlightAfter layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win
Candel Therapeutics’ CEO had to prioritize a phase 3 program amid layoffs and cuts, and an end-of-year clinical success was the redemption he was looking for.
By Michael Gibney • Jan. 9, 2025 -
Stock via Getty Images
10 of our most read articles of 2024
The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.
By Meagan Parrish • Dec. 20, 2024 -
Stock via Getty Images
Will the ‘anti-woke’ movement derail DEI efforts in pharma?
Amid the DEI backlash in corporate America, pharma leaders are quietly adjusting tactics.
By Meagan Parrish • Dec. 13, 2024 -
Permission granted by Regeneron
Q&ARegeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma
At this year’s ASH conference, Regeneron posted results for treatments that could disrupt the standards of care in two blood-related diseases.
By Michael Gibney • Dec. 12, 2024 -
Magdalena Wygralak via Getty Images
GSK’s multiple myeloma ADC Blenrep was pulled from the market. Now, it’s poised for a comeback.
GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could change the tide.
By Michael Gibney • Dec. 10, 2024 -
Permission granted by Astellas
Q&AHow Astellas juggles the moving parts of cancer precision medicine development
While developing its first-in-class gastric cancer drug Vyloy, Astellas had to coordinate with another pharma giant to usher the precision med into the market.
By Michael Gibney • Dec. 5, 2024 -
Noam Galai via Getty Images
With Makary set to face FDA commissioner hearings, how deep do his industry ties run?
Dr. Marty Makary’s conflicts of interest could come into question before he is confirmed as the next FDA commissioner.
By Amy Baxter • Dec. 4, 2024 -
Stock via Getty Images
Milk-based therapies could be coming. This biotech CEO is aiming to lead the way.
Intrinsic Medicine is entering phase 2 trials in Parkinson’s disease and IBS for its human milk oligosaccharide drug candidates next year.
By Amy Baxter • Dec. 2, 2024 -
Kevin Dietsch / Staff via Getty Images
How the incoming administration could impact FTC’s approach to pharma M&A
Pharma companies looking to get a break from the FTC under a new administration may be out of luck.
By Kelly Bilodeau • Nov. 26, 2024 -
iStock via Getty Images
Q&A // Biotech SpotlightAn RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond
Stoke Therapeutics is entering phase 3 with its RNA medicine designed to treat a rare epileptic condition.
By Michael Gibney • Nov. 26, 2024 -
Noam Galai via Getty Images
Johns Hopkins surgeon Makary is Trump’s pick to lead FDA
A prolific medical research and author, Martin Makary criticized the FDA and CDC for their decision-making during the pandemic, although he describes himself as pro-vaccine.
By Jonathan Gardner , Ned Pagliarulo • Nov. 25, 2024 -
Win McNamee via Getty Images
Trump nominees want to slash and burn agencies. Will RFK Jr. and Oz do the same in healthcare?
Both Trump appointees have promised to bring sweeping changes to several healthcare agencies.
By Amy Baxter • Nov. 25, 2024 -
Permission granted by AbbVie
What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine
AbbVie’s head of R&D cures has lofty ambitions to end diseases like HIV through a community of researchers that work as one.
By Michael Gibney • Nov. 19, 2024 -
Permission granted by Ron Tilles, Kevin Mercuri
ProfileLeft to clean up after ‘pharma bro’ Shkreli’s arrest, former Turing CEO Ron Tilles reckons with the past
While Martin Shkreli smirked his way through a public securities fraud investigation, Ron Tilles became interim CEO of Turing Pharmaceuticals, ready or not. Here’s his story.
By Michael Gibney • Nov. 14, 2024
